London, UK – 16 February 2026 – Prokarium, a clinical-stage biopharmaceutical company pioneering bacterial immunotherapy for the treatment of solid tumours, today announced that it will present interim clinical data at the 2026 European Association of Urology (EAU) Annual Congress, taking place in London, UK, 13th – 16th March, and the 2026 American Urological Association (AUA) Annual Meeting, taking place in Washington, DC, US, 15th – 18th May. Both conferences have accepted Prokarium’s work for oral presentation, which reflects the growing recognition of the high potential of its bacterial immunotherapy platform.
At EAU and AUA, Prokarium will share important emerging findings from the company’s ongoing Phase 1/1b clinical trial, PARADIGM-1 (NCT06181266), assessing the safety, pharmacology, and preliminary clinical efficacy of ZH9 treatment in patients with non-muscle invasive bladder cancer (NMIBC).
“We are delighted that our work has been selected for oral presentations at two of the most prestigious global urology meetings, in particular a podium presentation at the AUA” said Ibs Mahmood, CEO. “These invitations underscore the growing interest in our transformational treatment aiming to shift the standard of care for patients with bladder cancer, and I think the community is going to be very excited when they hear the results”
The 41st European Association of Urology Annual Congress Information:
- Presentation Title: PARADIGM 1 – A multi-center Phase 1 study evaluating the safety and clinical effect of a novel microbial immunotherapeutic (ZH9) in patients with relapsed NMIBC – A first interim review (Abstract ID: A0089)
- Session Title: High-risk NMIBC: Evolving BCG–immunotherapy strategies and technical advances in TURB (Abstract Session 05)
- Session Date and Time: Friday 13th March, 16:20 – 16:56
The American Urology Association Annual Meeting information:
- Presentation title: PARADIGM 1 – A multi-center Phase 1 study evaluating the safety and clinical effect of a novel microbial immunotherapeutic (ZH9) in patients with relapsed NMIBC – A first interim review (Abstract ID: 26-1116)
- Session Title: Podium Presentation PD09, Bladder Cancer: Non-Invasive III
- Session Date and Time: Saturday 16th May, 07:00 – 09:00
About Prokarium
Prokarium is a pioneering clinical-stage biotech company leveraging synthetic biology to create next generation bacterial immunotherapies. This is a new class of immunotherapy designed to deliver a broad and durable immune response with the potential to treat a wide range of different cancers. The lead program, ZH9, is currently in Phase 1 clinical trials in the US as a monotherapy treatment for NMIBC. Prokarium is based in London, UK. For further information, visit https://www.prokarium.com.
About ZH9
The investigational immunotherapy, ZH9, is being developed as an intravesical treatment for the prevention of recurrence in non-muscle invasive bladder cancer. The PARADIGM-1 study (NCT06181266) has completed enrolment across multiple centers in the United States.
For enquiries, please contact:
Kathryn Naylor
Kathryn.naylor@prokarium.com
www.prokarium.com
